PEB pacific edge limited

A research note from Jarden has valued NZX-listed biotech...

  1. 23 Posts.
    lightbulb Created with Sketch. 1
    A research note from Jarden has valued NZX-listed biotech Pacific Edge at double its current share price, citing the long-term commercial potential of its bladder cancer diagnostic technology, just need access to read full article - https://www.facebook.com/NBROnline/
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.